Meeting
2021 Genitourinary Cancers Symposium
Conditional progression-free survival in men on active surveillance for prostate cancer stratified by NCCN risk.
Authors
Andrew Gusev
Massachusetts General Hospital, Boston, MA
Andrew Gusev , Florian Rumpf , Keyan Salari , Jeffrey Twum-Ampofo , Matthew F Wszolek , Douglas M. Dahl , Michael L. Blute , Adam S. Feldman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Localized Disease
Track
Prostate Cancer - Localized
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 222)
DOI
10.1200/JCO.2021.39.6_suppl.222
Abstract #
222
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Gleason score upgrade among 10,282 men who underwent surgery as initial treatment in 2010: A population-based study.
First Author: Hong Zhang
Poster
2024 ASCO Genitourinary Cancers Symposium
Safety and clinical validity of tumor genomic testing for guiding active surveillance selection in men with NCCN intermediate-risk prostate cancer.
First Author: Lauren Lenz
Poster
2023 ASCO Genitourinary Cancers Symposium
Radiation therapy and irreversible electroporation for intermediate risk prostate cancer (RTIRE).
First Author: Timothy D McClure
Poster
2023 ASCO Genitourinary Cancers Symposium
Safety and quality of life analyses of apalutamide plus active surveillance vs active surveillance alone for low, intermediate risk prostate cancer.
First Author: Gwenaelle Gravis